Information  X 
Enter a valid email address

Eden Research plc (EDE)

  Print      Mail a friend       Annual reports

Thursday 30 June, 2011

Eden Research plc

Debt conversion, exercise of warrants and Direc...

                                                                                          30 June 2011

                                           EDEN RESEARCH PLC
                                         ("Eden" or "Company")

                    Debt conversion, exercise of warrants and Directors' Interests

Eden  Research plc, a leading UK agrochemical development company, is pleased to announce that  on  29
June  2011 Sir Ben Gill and Ken Brooks, Directors of the Company, converted GBP 15,000 and GBP 100,000
respectively of short term debt into 83,333 ordinary shares and 555,556 ordinary shares in the Company
at a price of 18p.

In addition, GBP 2,722,131 of long term debt has been converted into 15,122,951 ordinary shares in the
Company, also at a price of 18p.

Also,  warrants to subscribe for 555,556 ordinary shares in the Company have been exercised at a price
of 18p each. The net proceeds received by the Company from the exercise of the warrants are £100,000.

Following this debt conversion and warrant exercise, Eden has 99,303,596 ordinary shares in issue  and
the  Directors are now interested in a total of 2,290,782 ordinary shares, representing 2.31 per  cent
of the Company's enlarged issued share capital, as follows:

Director          No. of shares held     % of enlarged
                                         share capital
A Abrey                155,940                0.16
K Brooks              1,486,566               1.50
B Gill                 469,181                0.47
C Newitt               179,095                0.18

The Directors of Eden are responsible for the contents of this announcement.


Eden Research plc                                                        01993 862761
Clive Newitt, Managing Director

St Helens Capital Partners LLP                                           020 7368 6959
Mark Anwyl


Eden's strategy is focused on the development and commercialisation of its terpene-based encapsulation
technology  for  agricultural  and  non-agricultural  uses  through  appropriate  regional  or  global

Terpenes  are  natural  compounds which function as defence mechanisms in many plant  groups  and  are
released in response to infection, attack by pests, stress or mechanical injury. Terpenes are  already
widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically,  terpenes  have  had  limited commercial use in the agrochemical  sector  due  to  their
volatility,  phytotoxicity and poor solubility. Eden's platform encapsulation technology provides  the
unique,  natural  solution to these problems and enables terpenes to be used  as  effective,  low-risk

For more information about Eden, please visit

Eden Research plc								


a d v e r t i s e m e n t